Registration of APIs CMC information required for an IND
IND and NDA support Drug master files (DMF) filing
Synonyms/Alias | CXCL8 (54-72);CS-1050986 |
M.F/Formula | C107H173N33O30 |
M.W/Mr. | 2401.7 |
Sequence | One Letter Code:KENWVQRVVEKFLKRAENS Three Letter Code:Ac-DL-Lys-Glu-DL-Asn-Trp-DL-Val-Gln-DL-Arg-Val-DL-Val-Glu-DL-Lys-Phe-DL-Leu-Lys-DL-Arg-Ala-DL-Glu-Asn-DL-Ser-NH2 |
InChI | InChI=1S/C107H173N33O30/c1-53(2)46-72(98(163)128-64(29-17-20-42-109)91(156)126-66(31-22-44-119-106(115)116)89(154)122-57(9)88(153)124-69(34-38-81(146)147)95(160)136-76(50-80(113)145)101(166)137-77(52-141)87(114)152)132-99(164)73(47-59-24-12-11-13-25-59)133-92(157)65(30-18-21-43-110)125-94(159)71(36-40-83(150)151)131-104(169)85(55(5)6)140-105(170)86(56(7)8)138-97(162)67(32-23-45-120-107(117)118)127-93(158)68(33-37-78(111)143)130-103(168)84(54(3)4)139-102(167)74(48-60-51-121-62-27-15-14-26-61(60)62)134-100(165)75(49-79(112)144)135-96(161)70(35-39-82(148)149)129-90(155)63(123-58(10)142)28-16-19-41-108/h11-15,24-27,51,53-57,63-77,84-86,121,141H,16-23,28-50,52,108-110H2,1-10H3,(H2,111,143)(H2,112,144)(H2,113,145)(H2,114,152)(H,122,154)(H,123,142)(H,124,153)(H,125,159)(H,126,156)(H,127,158)(H,128,163)(H,129,155)(H,130,168)(H,131,169)(H,132,164)(H,133,157)(H,134,165)(H,135,161)(H,136,160)(H,137,166)(H,138,162)(H,139,167)(H,140,170)(H,146,147)(H,148,149)(H,150,151)(H4,115,116,119)(H4,117,118,120)/t57-,63?,64-,65?,66?,67?,68-,69?,70-,71-,72?,73-,74-,75?,76-,77?,84?,85?,86-/m0/s1 |
InChI Key | SRHYYZCRPIOFEW-ALFRKWSNSA-N |
1. Implications of ligand-receptor binding kinetics on GLP-1R signalling
2. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes
5. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us. We will endeavor to provide highly satisfying products and services.